http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103211779-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178 |
| filingDate | 2007-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103211779-B |
| titleOfInvention | Comprise alkalescence selectivity 5-hydroxy tryptamine 5-HT 3blocker and organic acid drug delivery system |
| abstract | A kind of pharmaceutical dosage form such as capsule, conventional tablet or Orally disintegrating tablet, it can in the mode of sustained release by pKn a for about 5 to 14 and dissolubility is no more than alkalescence nitrogenous (N) the selectivity 5-hydroxy tryptamine 5-HT of about 200 μ g/mL when pH is 6.8n 3 blocker is delivered in body, and this is suitable for dosage regimen once a day, and described pharmaceutical dosage form comprises at least one organic acid, and it makes described alkalescence selectivity 5-hydroxy tryptamine 5-HTn 3 blocker solubilising, described blocker is released in disadvantageous intestinal environment afterwards, and described blocker is almost insoluble in disadvantageous intestinal environment.Unit dosage forms can be made up of the granule of multiple many coatings (namely discharging pearl, sustained release pearl and/or one or more time-controlled release pearl groups immediately), it designs in the following manner: alkalescence blocker and organic acid close contact can not occur in processing and/or storage process, thus avoid forming sour additive compound in position, guarantee that acid can not exhaust before drug release terminates simultaneously. |
| priorityDate | 2006-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 87.